trial

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

NCTId NCT00455650
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 89 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2013-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
89 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2007-03
Primary completion
2013-01
Eligibility
ALL · 18 Years · 68 Years

Interventions & indications

Drugs
MecamylamineVarenicline

Sponsors

Massachusetts General HospitalLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
The Bowman Family FoundationCollaborator

Investigators

2
A. Eden Evins, MD, MPHPrincipal Investigator
Catherine Fullerton, M.D., M.P.H.Study Director

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
89
Phase
NA
Primary Completion Date
2013-01
Status
COMPLETED
relationships
The graph out of here
drug
Mecamylamine
drug
Varenicline
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
The Bowman Family Foundation
company
indication
Schizophrenia
indication
Cognition in Schizophrenia
indication
investigator
A. Eden Evins, MD, MPH
person
Catherine Fullerton, M.D., M.P.H.
person